Experts share the official predictions for RSV surge levels in 2024 and 2025, why the levels change each year, and how to ...
Zacks.com on MSN3h
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory NewsThis week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...
Respiratory season is among us, and Respiratory Syncytial Virus immunizations are now available for older adults and pregnant ...
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback